Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Brian Nicholas Cook

Daniel Kuzmich

Hossein Razavi

Can Mao

Pingrong Liu

Christian Harcken

Xiang Li

John Lord

Ingo Andreas Mugge

Brian Christopher Raudenbush

Hidenori Takahashi

Robert Owen Hughes

Thomas Martin Kirrane, Jr

Yunlong Zhang

Alan David Swinamer

Peter Allen Nemoto

Ho Yin Lo

Qiang Zhang

Fariba Soleymanzadeh

Darren DiSalvo

Shuang Liang

John D Huber

Thomas Wai-ho Lee

Jochen Neu

Michael Robert Turner

Ming-Hong Hao

Todd Bosanac

Sanxing Sun

Robert Sibley

Tina Marie Morwick

Lei Qiao

Christopher Ronald Sarko

Roger John Snow

Charles Lawrence Cywin

Jinhua Jeff Song

Erick Richard Roush Young

Ronald John Sorcek

Michael Jason Burke

Anne Bettina Eldrup

Daniel Richard Marshall

Stephane De Lombaert

Michel Jose Emmanuel

Rajashekhar Betageri

Michael Peter Winters

Jonathan Timothy Reeves

Zhulin Tan

Jin Mi Kim

Asitha Abeywardane

Wang Mao

Xin Guo

Joerg Bentzien

Sabine K Schlyer

Ji Wang

Jennifer A Kowalski

Kevin Chungeng Qian

Darren Todd Disalvo

Chuk Chui Man

Daniel Robert Fandrick

Steven John Taylor

Gregory Paul Roth

Yue Shen

Roman Wolfgang Fleck

Michael J Burke

Steven S Pullen

Kevin J Moriarty

Lana Louise Smith-Keenan

Darren Di Salvo

Alen David Swinamer

Jord Lord

Thomas Wei-Ho Lee

Celina Lasota

Thomas Martin Kirrane Jr

Thomas Martin Kirrane

Thomas Wai-Ho Lee

The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Heteroaromatic compounds as Vanin inhibitors

The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Compounds as modulators of RORC

The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Benzimidazolone chymase inhibitors

Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar, Ar, R, X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists

Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I). 

Heterocyclic compounds as CCR1 receptor antagonists

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Rho kinase inhibitors

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.  Also disclosed are methods of making and methods of using same.

Pyrazolopiperidine compounds as CCR1 receptor antagonists

Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Pyrazole compounds as CCR1 antagonists

Compounds of the formula (I) wherein R, R, R, R, R, R, W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of Urotensin II with its receptor, including cardiovascular diseases. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds, and intermediates useful in these processes.

Urotensin II receptor antagonists

Azaindazole compounds as CCR1 receptor antagonists

Disclosed are substituted benzimidazole compounds of formula (I): wherein R, R, R, Rand Xare defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

Substituted benzimidazole compounds

Growing community of inventors

Danbury, CT, United States of America

Brian Nicholas Cook